Related Experiment Video
Updated: Sep 15, 2025
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Expression and Clinical Significance of PIM1 in Newly Diagnosed Patients with Acute Myeloid Leukemia
Background:
This study aimed to evaluate the expression level of proviral integration of Moloney murine leukemia virus 1 (PIM1) in acute myeloid leukemia (AML) and to investigate its clinical significance, including its expression and prognostic value in AML.
Methods:
Bone marrow samples were obtained from 80 newly diagnosed AML patients (observation group) and 20 healthy individuals (control group). Clinical and pathological characteristics of AML patients were collected. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to measure PIM1 expression levels in the two groups. The association between PIM1 expression and clinicopathological characteristics and prognosis in AML patients was analyzed. Kaplan-Meier survival curves were used to assess the impact of PIM1 expression on overall survival (OS), while Cox proportional hazards regression was employed to identify prognostic factors in AML patients.
Results:
PIM1 expression was significantly higher in AML patients compared to the control group (p < 0.0001). Within the AML cohort, the high PIM1 expression group showed significant differences in gender distribution, FAB classification, treatment response, and prognosis compared to the low PIM1 expression group (p < 0.05). The OS of patients with high PIM1 expression was markedly shorter than that of patients with low PIM1 expression (p < 0.05). Furthermore, high PIM1 expression was identified as an independent risk factor for poor prognosis in AML patients.
Conclusions:
PIM1 is overexpressed in AML patients and is associated with adverse clinicopathological characteristics and poor prognosis. PIM1 may serve as a prognostic biomarker and a potential therapeutic target in AML.
Insights
Proviral integration of Moloney murine leukemia virus 1 (PIM1) is elevated in acute myeloid leukemia (AML) patients. High PIM1 expression correlates with adverse characteristics and poorer prognosis, identifying it as a potential biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
- Proviral integration of Moloney murine leukemia virus 1 (PIM1) is a proto-oncogene implicated in cell proliferation and survival.
Purpose of the Study:
- To evaluate PIM1 expression levels in AML patients.
- To investigate the clinical significance and prognostic value of PIM1 in AML.
Main Methods:
- Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to measure PIM1 expression in 80 AML patients and 20 healthy controls.
- Clinicopathological data and survival outcomes were analyzed in relation to PIM1 expression levels.
- Kaplan-Meier and Cox regression analyses assessed the prognostic impact of PIM1.
Main Results:
- PIM1 expression was significantly higher in AML patients than in controls (p < 0.0001).
- High PIM1 expression was associated with specific FAB classifications, treatment response, and poorer prognosis (p < 0.05).
- Overall survival was markedly shorter in patients with high PIM1 expression, identifying it as an independent risk factor for poor prognosis.
Conclusions:
- PIM1 is overexpressed in AML and linked to adverse clinicopathological features and outcomes.
- PIM1 demonstrates potential as a prognostic biomarker for AML.
- PIM1 may represent a viable therapeutic target for AML treatment.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
